MEDIPOST Co. Ltd
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthrit… Read more
MEDIPOST Co. Ltd (078160) - Net Assets
Latest net assets as of September 2025: ₩265.17 Billion KRW
Based on the latest financial reports, MEDIPOST Co. Ltd (078160) has net assets worth ₩265.17 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩374.57 Billion) and total liabilities (₩109.40 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩265.17 Billion |
| % of Total Assets | 70.79% |
| Annual Growth Rate | 6.24% |
| 5-Year Change | 116.74% |
| 10-Year Change | 72.44% |
| Growth Volatility | 25.37 |
MEDIPOST Co. Ltd - Net Assets Trend (2011–2024)
This chart illustrates how MEDIPOST Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MEDIPOST Co. Ltd (2011–2024)
The table below shows the annual net assets of MEDIPOST Co. Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩252.60 Billion | -19.47% |
| 2023-12-31 | ₩313.66 Billion | +74.28% |
| 2022-12-31 | ₩179.97 Billion | +12.85% |
| 2021-12-31 | ₩159.48 Billion | +36.84% |
| 2020-12-31 | ₩116.54 Billion | +4.44% |
| 2019-12-31 | ₩111.59 Billion | -12.01% |
| 2018-12-31 | ₩126.81 Billion | +21.41% |
| 2017-12-31 | ₩104.45 Billion | -27.12% |
| 2016-12-31 | ₩143.31 Billion | -2.17% |
| 2015-12-31 | ₩146.48 Billion | +24.84% |
| 2014-12-31 | ₩117.34 Billion | -0.07% |
| 2013-12-31 | ₩117.42 Billion | +0.17% |
| 2012-12-31 | ₩117.23 Billion | +1.90% |
| 2011-12-31 | ₩115.04 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to MEDIPOST Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 934.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩350.60 Billion | 139.51% |
| Total Equity | ₩251.31 Billion | 100.00% |
MEDIPOST Co. Ltd Competitors by Market Cap
The table below lists competitors of MEDIPOST Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Heartland Banccorp
OTCQX:HLAN
|
$192.42 Million |
|
FB Bancorp, Inc. Common Stock
NASDAQ:FBLA
|
$192.45 Million |
|
DRB - Hicom Bhd
KLSE:1619
|
$192.48 Million |
|
Kepler Weber S.A
SA:KEPL3
|
$192.56 Million |
|
Hunan Zhenghong Science and Technology Develop Co Ltd
SHE:000702
|
$192.35 Million |
|
Evans Bancorp Inc
NYSE MKT:EVBN
|
$192.32 Million |
|
D&L Industries Inc
PINK:DALQF
|
$192.30 Million |
|
Sino-Argi Leading Biosciences
SHG:603970
|
$192.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MEDIPOST Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 311,554,525,920 to 251,310,495,620, a change of -60,244,030,300 (-19.3%).
- Net loss of 62,524,995,360 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-62.52 Billion | -24.88% |
| Other Changes | ₩2.28 Billion | +0.91% |
| Total Change | ₩- | -19.34% |
Book Value vs Market Value Analysis
This analysis compares MEDIPOST Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.40x to 3.01x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩9258.61 | ₩22200.00 | x |
| 2017-12-31 | ₩6747.79 | ₩22200.00 | x |
| 2018-12-31 | ₩8182.15 | ₩22200.00 | x |
| 2019-12-31 | ₩7199.82 | ₩22200.00 | x |
| 2020-12-31 | ₩7519.53 | ₩22200.00 | x |
| 2021-12-31 | ₩9877.81 | ₩22200.00 | x |
| 2022-12-31 | ₩11147.01 | ₩22200.00 | x |
| 2023-12-31 | ₩9136.82 | ₩22200.00 | x |
| 2024-12-31 | ₩7370.07 | ₩22200.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MEDIPOST Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -88.49%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.65x
- Recent ROE (-24.88%) is below the historical average (-2.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 3.85% | 12.39% | 0.27x | 1.15x | ₩-7.03 Billion |
| 2012 | 1.46% | 4.16% | 0.30x | 1.18x | ₩-9.95 Billion |
| 2013 | 0.86% | 2.40% | 0.28x | 1.25x | ₩-10.65 Billion |
| 2014 | -1.59% | -4.47% | 0.22x | 1.60x | ₩-13.51 Billion |
| 2015 | 1.90% | 7.40% | 0.21x | 1.25x | ₩-11.87 Billion |
| 2016 | -3.74% | -18.73% | 0.16x | 1.25x | ₩-19.70 Billion |
| 2017 | -0.91% | -2.25% | 0.29x | 1.38x | ₩-11.39 Billion |
| 2018 | -1.58% | -4.52% | 0.25x | 1.39x | ₩-14.69 Billion |
| 2019 | -12.65% | -30.82% | 0.21x | 1.92x | ₩-25.28 Billion |
| 2020 | -1.63% | -3.90% | 0.22x | 1.89x | ₩-13.55 Billion |
| 2021 | -0.43% | -1.25% | 0.22x | 1.59x | ₩-16.63 Billion |
| 2022 | 1.71% | 4.78% | 0.16x | 2.21x | ₩-14.93 Billion |
| 2023 | 1.87% | 8.51% | 0.15x | 1.44x | ₩-25.32 Billion |
| 2024 | -24.88% | -88.49% | 0.17x | 1.65x | ₩-87.66 Billion |
Industry Comparison
This section compares MEDIPOST Co. Ltd's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $45,958,290,873
- Average return on equity (ROE) among peers: -9.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MEDIPOST Co. Ltd (078160) | ₩265.17 Billion | 3.85% | 0.41x | $192.41 Million |
| Macrogen Inc (038290) | $118.01 Billion | 2.24% | 0.52x | $99.40 Million |
| Panagene Inc (046210) | $30.94 Billion | 0.00% | 0.90x | $29.96 Million |
| Cell Biotech Co. Ltd (049960) | $52.36 Billion | 19.87% | 0.10x | $43.10 Million |
| Bioneer Corporation (064550) | $26.11 Billion | -55.21% | 1.44x | $175.97 Million |
| Biotoxtech Co. Ltd (086040) | $41.14 Billion | 17.29% | 1.21x | $23.35 Million |
| Peptron Inc (087010) | $7.18 Billion | -42.42% | 0.61x | $3.92 Billion |